Attached files
| file | filename |
|---|---|
| EXCEL - IDEA: XBRL DOCUMENT - Acer Therapeutics Inc. | Financial_Report.xls |
| 10-Q - OPEXA THERAPEUTICS, INC. 10-Q - Acer Therapeutics Inc. | a50472836.htm |
| EX-31.1 - EXHIBIT 31.1 - Acer Therapeutics Inc. | a50472836ex31_1.htm |
| EX-32.1 - EXHIBIT 32.1 - Acer Therapeutics Inc. | a50472836ex32_1.htm |
| EX-31.2 - EXHIBIT 31.2 - Acer Therapeutics Inc. | a50472836ex31_2.htm |
EXHIBIT 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO SECTION 906
OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Opexa Therapeutics, Inc. (the “Company”) on Form 10-Q for the period ended September 30, 2012 (the “Report”), as filed with the Securities and Exchange Commission on the date hereof, I, David E. Jorden, Acting Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to §906 of the Sarbanes-Oxley Act of 2002, to the best of my knowledge, that:
|
1.
|
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
2.
|
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
Date: November 14, 2012
|
By:
|
/s/ David E. Jorden
|
|
David E. Jorden
Acting Chief Financial Officer
(Principal Financial and Accounting Officer)
|